Key result
Alteplase reduces death or dependency after acute ischemic stroke despite intracranial hemorrhage risks.
Why the study?
Further data from randomized controlled trials are needed to determine which acute ischemic stroke patients benefit most from alteplase and whether more patients could be treated.
Answers are grounded in this paper and cite their sources.
Further randomized trials needed for alteplase beyond age 80 or 3-hour window; leaves open expanded indications in acute stroke.
Alteplase is the only licensed thrombolytic agent for the treatment of acute ischemic stroke. The body of evidence to date suggests that it reduces the number of stroke patients who are dead or dependent at follow up, despite the risk of intracranial hemorrhage. However, in Europe, the license has only been granted for people aged under 80 years who fulfil specific criteria and who can be seen and treated within 3 h of symptom onset. There is a need for further data from randomized controlled trials to determine more precisely which patients are most likely to benefit and whether a wider variety of patients could be treated.
No takes yet. Share an insight, caveat, or question.
Kane et al. (2005) conducted a review in Acute ischemic stroke. Alteplase was evaluated on Death or dependency at follow up. Alteplase reduces death or dependency after acute ischemic stroke despite intracranial hemorrhage risks, but further randomized data are needed to optimize patient selection.
Synapse has enriched 10 related papers. Consider them for comparative context: